High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
ID: 351847Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351847

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-060.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use disorders. This initiative invites interdisciplinary research teams of three to six principal investigators to address critical research questions that could lead to new prevention strategies, treatments, and potential cures for HIV among individuals who use addictive substances. The program emphasizes collaboration and inclusivity, requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) alongside their proposals. Funding is available for up to $3 million over five years, with individual awards capped at $1.5 million per year. Interested applicants should note that a letter of intent is recommended 30 days prior to the application deadline of February 11, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-060-Full-Announcement.html
    RFA-DA-25-060.html
    The National Institutes of Health (NIH) has issued a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting research at the intersection of HIV and substance use disorders. The initiative invites interdisciplinary research teams of three to six principal investigators (PD/PIs) to tackle challenging research questions that could lead to new preventive measures, treatments, and potential cures for HIV among individuals who use addictive substances. The initiative emphasizes the need for a collaborative approach and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to ensure inclusivity in research. Funding includes up to $3 million for projects over five years, with individual award budgets not exceeding $1.5 million per year. Applications must adhere to strict submission guidelines and deadlines, with a letter of intent recommended 30 days prior to the application due date. The research projects should focus on integrating diverse scientific methodologies and transformative goals that significantly advance the field of HIV research. Non-responsive applications will be withdrawn, reinforcing the emphasis on aligning with NIH and NIDA priorities. The program seeks to build innovative research capabilities to address critical health disparities related to HIV among substance users.
    Similar Opportunities
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances" under the R34 planning grant mechanism. This initiative aims to encourage formative research and the development of innovative interventions that target HIV prevention and care, particularly for populations that engage in substance use, addressing critical gaps in HIV care and prevention. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofit entities, and tribal governments, with grants available for up to $450,000 over three years. The application cycle begins on April 7, 2025, with subsequent due dates throughout the year, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HIV Prevention and Alcohol (R01 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at expanding HIV prevention strategies among populations affected by alcohol use. This initiative encourages research projects that explore the relationship between alcohol consumption and HIV risk behaviors, focusing on areas such as Pre-exposure Prophylaxis (PrEP) utilization, Treatment as Prevention (TasP), and the integration of preventive intervention strategies. The program is particularly significant for addressing health disparities among high-risk groups, including men who have sex with men (MSM) and women with high-risk partners. The NIH anticipates funding between $2 million for 2 to 4 awards, with a project period of up to five years. Interested applicants can submit their proposals through the NIH ASSIST system or Grants.gov, and should direct inquiries to grantsinfo@nih.gov. The application deadline is May 7, 2026.
    HIV Prevention and Alcohol (R01 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HIV Prevention and Alcohol (R01 Clinical Trials Optional)" aimed at enhancing the HIV/AIDS prevention toolkit for populations impacted by alcohol use. This initiative seeks to integrate effective prevention and treatment interventions while developing and testing new strategies to address the behavioral and biological risks associated with HIV acquisition, particularly among high-risk groups such as men who have sex with men and transgender individuals. The anticipated funding for fiscal year 2025 is $2 million, with 2-4 awards expected, and applications must be submitted through Grants.gov by May 7, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAS-25-208.html.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    HIV Prevention and Alcohol (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), has announced a Notice of Funding Opportunity (NOFO) titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)." This initiative aims to enhance the HIV prevention toolkit for populations affected by alcohol consumption, focusing on the integration of effective prevention and treatment interventions to reduce the incidence of new HIV infections. The program is particularly relevant for high-risk groups, including men who have sex with men, transgender individuals, and others impacted by alcohol-related HIV transmission, emphasizing the need for innovative strategies to address health disparities. The funding opportunity offers a total estimated program funding of $1.5 million for 2-4 awards, with individual project budgets capped at $450,000, and applications are due by May 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and should refer to the full announcement for detailed application guidelines.
    Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data." This initiative invites applications that propose innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to investigate the etiology and epidemiology of substance use behaviors and related disorders, including HIV prevention and health service utilization. The program aims to leverage public datasets to enhance understanding of substance use trajectories and effective prevention strategies, particularly focusing on underrepresented populations and health disparities. A total funding commitment of $2 million is available for fiscal year 2026, with applications due by January 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Avant Garde award for Investigators conducting high risk/high reward research on HIV and Substance Use (or Substance Use Disorders)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the Avant Garde Award for Investigators conducting high-risk, high-reward research focused on HIV and Substance Use Disorders (SUDs). This grant program aims to support innovative scientists proposing transformative approaches to significant challenges in biomedical and behavioral research related to HIV in the context of substance use. The program particularly encourages early-stage investigators to develop collaborative and impactful research projects, with applications expected to open in March 2026 and close in August 2026. For further inquiries, interested applicants can contact Vasundhara Varthakavi at vasundhara.varthakavi@nih.gov or by phone at 301-443-2146.
    Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)" aimed at supporting research into effective interventions for substance use disorders (SUDs) and overdose. This cooperative agreement encourages applications for preclinical and clinical studies focusing on pharmacotherapies, device-based treatments, digital therapeutics, and behavioral interventions, with the goal of advancing these interventions towards regulatory approval or clinical adoption. The funding amount can reach up to $3 million, and applications are due by 5:00 PM local time, with multiple submission cycles from October 2025 to August 2028. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    HIV Prevention and Alcohol (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HIV Prevention and Alcohol (R34 Clinical Trials Optional)" aimed at expanding the HIV/AIDS prevention toolkit among populations impacted by alcohol use. This grant seeks to support research that integrates effective prevention and treatment interventions while addressing the behavioral and biological risks associated with alcohol consumption, particularly among high-risk groups. The initiative is crucial for informing the design of future clinical trials focused on HIV prevention, with an anticipated funding amount of approximately $1.5 million for 2-4 awards. Interested applicants, including higher education institutions and community organizations, must submit their proposals by September 7, 2025, and can find additional information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.